US › Healthcare

Vericel Corp Ord (VCEL)

US · Healthcare · Biotechnology

$46.34+0.63%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$68.4M
Revenue YoY
+30.1%
Net profit
$-6.3M
Profit YoY
+44.0%
EPS
$-0.12
EPS estimate
$-0.16
Net margin
-9.2%

EPS came in at -0.12 against a street estimate of -0.16 — a beat of 25.0%.

Key statistics

Market cap
$2.38B
P/E
108.4
Forward P/E
98.0
P/B
6.69
Book value
$6.98
EPS (TTM)
$0.43
52-week high
$49.32
52-week low
$28.95
50-day MA
$41.14
200-day MA
$37.25
Beta
1.07

Analyst view

Analysts rate Vericel Corp Ord a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $57.14.

Shareholding

Insiders
1.19%
Institutions
112.94%

Largest institutional holders

FundStake
BlackRock Inc15.21%
Vanguard Group Inc7.02%
State Street Corp6.17%
Congress Asset Management Company, LLP5.71%
Soleus Capital Management, L.P.4.99%
Conestoga Capital Advisors, LLC4.82%
Vanguard Capital Management, LLC4.37%
William Blair Investment Management, LLC3.59%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vericel Corp Ord — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.